ALK (Anaplastic Lymphoma Kinase)

ALK

Receptor tyrosine kinase rearranged in ~5% of NSCLC.

Chức năng

ALK inhibitors (crizotinib, alectinib, lorlatinib) achieve high response rates in ALK-rearranged NSCLC.

Related Targets